Indicator Explainer
Tumor Necrosis Factor
Tumor necrosis factor (233 aa, ~26 kDa) is encoded by the human TNF gene. This protein is involved in the induction of cytokine expression, the stimulation of cell proliferation and the positive regulation of cell differentiation.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C20535. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-19. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
Related Tests
Tests that measure or involve this indicator.
References
- NCI Thesaurus 26.09d — Tumor Necrosis Factor (C20535)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C20535. NCI definition, reproduced without modification under CC BY 4.0.
- [Advances in the effects of obesity on anti-tumor necrosis factor therapy in children with inflammatory bowel disease]. — Zhonghua Er Ke Za Zhi, 2026-10-15 (PMID 42876110; literature)
- Patients with cyclops syndrome exhibit elevated synovial fluid interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels and disorganized collagen remodelling within the lesion: A histological and molecular study. — J Exp Orthop, 2026-10-17 (PMID 42893231; literature)
- Combined crocin and treadmill exercise regulate cardiac MicroRNA-23b, nuclear factor Erythroid 2-related factor 2, and tumor necrosis factor-alpha in experimental type 2 diabetes mellitus. — Mol Biol Rep, 2026-10-29 (PMID 42955468; literature)
- Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis. — Inflamm Bowel Dis, 2026-10-29 (PMID 42955073; literature)